 SAN FRANCISCO, March 14, 2022 PRNewswire -- Nektar Therapeutics NASDAQ:NKTR will hold an analyst and investor conference call with Nektar management today, Monday, March 14, 2022, at 5:00 a.m. Pacific Standard Time PST, following this mornings update from Bristol-Myers Squibb and Nektar on the pivotal Phase 3 PIVOT IO-001 study in previously untreated unresectable or metastatic melanoma. 